Clinical implications of DLL4 expression in gastric cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Ishigami, Sumiya ^a   Arigami, Takaaki ^a   Uenosono, Yoshikazu ^a   Okumura, Hiroshi ^a   Kurahara, Hiroshi ^a   Uchikado, Yasuto ^a   Setoyama, Tetsuro ^a   Kita, Yoshiaki ^a   Kijima, Yuko ^a   Nishizono, Yuka ^a   Nakajo, Akihiro ^a   Owaki, Tetsuro ^a   Ueno, Shinichi ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Delta like ligand 4; Gastric cancer; Lymph node metastases; Lymphatic invasion; Peritumoral stroma

Indexed keywords

DELTA LIKE LIGAND 4; LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN TISSUE; CANCER CELL; CANCER CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH CANCER; STROMA CELL; TUMOR GROWTH; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; STROMAL CELLS;

EID: 84880896817     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-46     Document Type: Article

References (27)

1. Surgery for gastric cancer: an evidence-based perspective. D'souza MA, Singh K, Shrikhande SV, J Cancer Res Ther 2009 5 225 231 10.4103/0973-1482.59891 20160354
2. Treatment options for surgically resectable gastric cancer. Rajdev L, Curr Treat Options Oncol 2010 11 14 23 10.1007/s11864-010-0117-1 20358316
3. The essentials of locoregional control in the treatment of gastric cancer. den Dulk M, Verheij M, Cats A, Jansen EP, Hartgrink HH, Van de Velde CJ, Scand J Surg 2006 95 236 242 17249271
4. Tumor angiogenesis: therapeutic implications. Folkman J, N Engl J Med 1971 285 1182 1186 10.1056/NEJM197111182852108 4938153
5. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Sato Y, Int J Clin Oncol 2003 8 200 206 10.1007/s10147-003-0342-8 12955574
6. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Fernando NH, Hurwitz HI, Oncologist 2004 9 11 18 10.1634/theoncologist.9-suppl-1-11 15178811
7. VEGF-targeting therapy for breast cancer. Sledge GW Jr, J Mammary Gland Biol Neoplasia 2005 10 319 323 10.1007/s10911-006-9005-5 16924373
8. Bevacizumab and chemotherapy improves survival in NSCLC. Kerr C, Lancet Oncol 2005 6 266 15889503
9. Anti-angiogenic strategies in gastrointestinal malignancies. Whisenant J, Bergsland E, Curr Treat Options Oncol 2005 6 411 421 10.1007/s11864-005-0044-8 16107244
10. Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP, J Clin Oncol 2011 29 868 874 10.1200/JCO.2010.32.0770 21189380
11. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, Harris AL, Cancer Res 2011 71 6073 6083 10.1158/0008-5472.CAN-11-1704 21803743
12. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Dufraine J, Funahashi Y, Kitajewski J, Oncogene 2008 27 5132 5137 10.1038/onc.2008.227 18758482
13. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M, Adams RH, Cell 2009 137 1124 1135 10.1016/j.cell.2009.03.025 19524514
14. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M, Nature 2006 444 1083 1087 10.1038/nature05313 17183323
15. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G, Nature 2006 444 1032 1037 10.1038/nature05355 17183313
16. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston G, Fox SB, Harris AL, Br J Cancer 2009 101 1749 1757 10.1038/sj.bjc.6605368 19844231
17. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li JL, Allen P, Leek R, Noguera-Troise I, Gatter KC, Thurston G, Harris AL, Am J Pathol 2010 176 2019 2028 10.2353/ajpath.2010.090908 20167860
18. Japanese Classification of Gastric Carcinoma -2nd English Edition. Japanese Gastric Cancer Association, Gastric Cancer 1998 1 10 24 11957040
19. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D, Differentiation 2001 69 135 144 10.1046/j.1432-0436. 2001.690207.x 11798067
20. Upregulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Patel NS, Dobbie MS, Rochester M, et al. Clin Cancer Res 2006 12 4836 4844 10.1158/1078-0432.CCR-06-0285 16914569
21. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A, Feldmann G, Clin Cancer Res 2009 15 2291 2301 10.1158/1078-0432.CCR-08-2004 19258443
22. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H, Clin Cancer Res 2011 17 372 381 10.1158/1078-0432.CCR-10-1791 21224365
23. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL, Cancer Res 2007 67 11244 11253 10.1158/0008-5472.CAN-07-0969 18056450
24. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC, Li AF, Wang AM, Kuo ML, Chi CW, Cancer Res 2009 69 5039 5048 19491270
25. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST, Mol Cancer Ther 2012 11 1650 1660 10.1158/1535-7163.MCT- 11-1027 22679110
26. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Kuhnert F, Kirshner JR, Thurston G, Vasc Cell 2011 3 1 20 10.1186/2045-824X-3-20 21923938
27. Prognostic impact of Notch ligands and receptors in non-small cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM, Cancer 2010 116 5676 5685 10.1002/cncr.25551 20737536